European Journal of Cardiovascular Medicine

Background: The fourth most common cause of death from malignancies, pancreatic cancer is a serious cause of morbidity and mortality. [1] This low survival rate is due to late presentation, vague indications and symptoms, and insufficient diagnostic and treatment options. The effectiveness of treatment approaches can be significantly increased by correctly diagnosing benign and malignant diseases of the pancreas. Objectives: To study diagnostic efficacy of EUS-FNA with importance of cytopathology and correlating with histopathology and biochemical markers. Material & Methods: Study Design: Retrospective Hospital based observational study. Study area: Department of Pathology (Histopathology laboratory), NIMS, Hyderabad. Study Period: January 2019 – December 2022. (3 years) Study population: Sample size: study consisted a total of 172 cases. Sampling method: Simple random method. Study tools and Data collection procedure: Clinical information, results from lab tests, and reports from cytopathology and imaging studies were all retrieved for each patient. To determine the location, size, and features of the pancreatic lesions, imaging reports from sonography, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasonography (USG) were analyzed. The location, size, and features of the pancreatic lesions were evaluated using computed tomography (CT) and magnetic resonance imaging (MRI). Atrained pathologist and a technician from the on-site pathology team assisted with the EUS instruction for each FNA. Results: The mean age of the study subjects was 53.7 ± 13.33 years. Most (52.9%) of the subjectswereintheagegroupof41-60years, followed by 30.8% were in 61–80 years group. Only2.3% were in < 20yearsagegroup.Ourstudyalsohadresultswithsensitivity, specificity, PPV, and NPV of 58.2%, 82.3%, 85%, and 53.5%, respectively. Conclusion: The results of this study demonstrated that EUS-FNA had good sensitivity, specificity, PPV, and NPV in the detection of solid and cystic pancreatic cancer. If necessary, a composite of the EUS-FNA cytology, cell block preparation, and immunohistochemistry results can be used to make the final diagnosis. This information may then be used to guide both surgeons' and oncologists' treatment strategies.